Oral blockade of the platelet glycoprotein IIb/IIIa receptor: fact or fancy?
Currently available antiplatelet agents are limited in the scope and magnitude of platelet inhibition. Orally active platelet glycoprotein IIb/IIIa antagonists are currently in clinical testing. These agents may extend platelet inhibition and clinical benefit from parenteral glycoprotein IIb/IIIa antagonists. The most common adverse side effect is mucocutaneous bleeding, which is related to the magnitude and duration of platelet inhibition. Point-of-care monitoring of platelet function may enhance safety and efficacy of oral platelet GP IIb/IIIa blockade. Because aspirin, ticlopidine, and clopidogrel have proved beneficial in reducing vascular ischemic events, oral platelet glycoprotein IIb/IIIa inhibitors, which provide more marked platelet inhibition, are positioned to provide even greater clinical benefit if tolerated.
Kereiakes
D J
DJ
Carl and Edyth Lindner Center for Clinical Cardiovascular Research, Cincinnati, Ohio, USA.
D000077284:Abciximab; D000284:Administration, Oral; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D001550:Benzamidines / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004357:Drug Synergism; D004844:Epistaxis / Q000139:chemically induced; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage / Q000009:adverse effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D001550:Benzamidines; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; C091295:xemilofiban; D001241:Aspirin; D000077284:Abciximab